Cannabis Law and Access in Nigeria

Thirty-eight pages into Nigeria's National Drug Law Enforcement Agency (NDLEA) annual report for 2022, there's a table that stops you cold: cannabis seizure volumes outpace every other controlled substance combined, by a factor of roughly twelve. I flagged this sitting at my desk in Canberra on a grey Tuesday, surrounded by the kind of vintage survey maps that make my partner question my priorities. The scale of it points to something worth understanding properly , a legal framework that is, on paper, among the strictest in Africa, yet sits against an agricultural and cultural reality that tells a very different story.

The federal scheduling baseline

Nigeria's primary instrument is the National Drug Law Enforcement Agency Act (Cap N30, Laws of the Federation of Nigeria 2004), read alongside the Dangerous Drugs Act (Cap D1). Under these statutes, cannabis , listed as Indian hemp in Nigerian legal language , is a controlled substance. Possession, cultivation, sale, and distribution are all criminal offences. There is no federally recognised recreational status, and there is no adult-use regime of any kind. On the formal hierarchy, this places Nigeria closer to its regional neighbours who have not moved on reform than to, say, South Africa, where the Constitutional Court's 2018 Minister of Justice and Constitutional Development v Prince decision decriminalised private adult use.

Penalties under the NDLEA Act are serious. Trafficking offences attract custodial sentences measured in years, and for large quantities the law provides for very lengthy terms; in some provisions, life imprisonment is available to sentencing courts. The NDLEA itself, established in 1989, operates as the primary enforcement body with powers to investigate, arrest, and prosecute.

Cannabis and Nigerian agricultural history

Here is where the legal picture gets complicated. Cannabis sativa has a long documented presence across Nigeria's middle belt and south-south zones. The plant, locally called igbo, ganja, or wee-wee depending on region, was cultivated for fibre and seed uses well before modern prohibition frameworks arrived. Colonial-era ordinances, mirroring British imperial drug policy, began targeting it from the 1930s onwards. Post-independence Nigeria retained and then strengthened those provisions.

That history matters because the conversation around industrial hemp sits awkwardly against a scheduling framework that does not currently draw a formal THC-threshold distinction for low-potency cultivars, unlike the legislative models in Canada or the European Union's Common Agricultural Policy. If you are across the Australian system; where the Narcotic Drugs Act 1967 and the Industrial Hemp Act frameworks in various states distinguish low-THC hemp from higher-potency cannabis, the absence of that line in Nigeria is a notable structural gap.

Is there any medical access pathway?

This is the question I get most from readers who are familiar with how access works in places like Australia (via the Special Access Scheme or the Authorised Prescriber pathway) or Canada (via the federal Access to Cannabis for Medical Purposes regulations). The short answer for Nigeria: no comparable federal medical cannabis access framework exists as of mid-2025.

There have been legislative proposals. In 2020 a bill to amend the NDLEA Act and create a regulated medical and industrial cannabis framework was introduced to the National Assembly. It did not pass. A revised version was reportedly under consideration in subsequent sessions, but no federal legislation creating a licensed medical access scheme has been enacted. Researchers interested in the pharmacology, including how cannabidiol differs mechanistically from psychoactive cannabinoids at the CB1 receptor; find themselves in a country where that scientific conversation and the legal framework remain almost entirely disconnected.

Some state-level initiatives have drawn attention. Ondo State's government announced an Ondo State Cannabis Regulatory Agency framework around 2022, aimed at licensing cultivation for export under a controlled scheme. The legality of this under federal law is, to be honest, not fully resolved. Nigeria operates a federal system, but drug control is a concurrent legislative matter and the NDLEA's federal mandate is broad. Whether a state-issued licence provides meaningful protection against federal enforcement is exactly the kind of ambiguity that makes regulatory researchers nervous. And should make farmers nervous too.

Enforcement reality versus written law

A gap between formal law and enforcement intensity is not unique to Nigeria, you see versions of it in many jurisdictions. But it is pronounced here. Cannabis cultivation occurs at significant scale in states including Edo, Delta, Cross River, and Ondo. The NDLEA conducts regular eradication operations; its published seizure statistics confirm ongoing enforcement activity. At the same time, the sheer agricultural spread of cultivation suggests resources are not close to matching the statutory ambition.

I'd argue the enforcement-reality gap is one reason why reform advocates frame the issue partly in economic terms, asking what regulated export revenue might look like relative to the current picture of criminalisation without control. That's a policy argument I won't adjudicate here, but it is the lens through which most of the reform bills have been pitched to the National Assembly.

International treaty obligations

Nigeria is a signatory to the three main United Nations drug control conventions: the Single Convention on Narcotic Drugs 1961 (as amended by the 1972 Protocol), the Convention on Psychotropic Substances 1971, and the United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances 1988. Cannabis appears in Schedule I and Schedule IV of the 1961 Single Convention; the most restrictive classification, though the UN Commission on Narcotic Drugs voted in December 2020 to remove cannabis from Schedule IV, a decision that opens space for member states to develop medical frameworks without formally violating treaty obligations.

That 2020 CND vote is a significant piece of context. It does not legalise anything domestically anywhere, but it does remove the treaty-level argument against medical cannabis frameworks. Nigeria has not moved to create one federally, but the international scaffolding that blocked reform has shifted. For readers who follow how Australia's own scheduling decisions interact with those same treaties, the Poisons Standard's placement of cannabis-derived products as Schedule 8 controlled drugs has its own treaty dimension; that shift at the UN level is worth tracking.

What researchers and science communicators should understand

From a science-communication standpoint, the Nigerian context matters for a few reasons. First, Cannabis sativa cultivars grown across West Africa are historically distinct from those developed in North American or European commercial programmes. Phytochemical profiles, including the mix of cannabinoids beyond THC and CBD, and the full range of terpenes that characterise individual chemotypes, differ meaningfully across geographic origins. Second, any legitimate research on those profiles requires a legal framework that permits sample collection, analysis, and publication. Nigeria currently has no such framework, which leaves a gap in the global phytochemical literature.

For Australian readers curious about how access and research frameworks elsewhere compare to mechanisms like the Special Access Scheme, Nigeria illustrates what a high-restriction, no-access baseline looks like in practice: significant agricultural presence, active enforcement, a proposed but unenacted medical framework, and state-level experiments whose federal legality remains uncertain.

The reform trajectory; if it comes, will most likely move through the National Assembly rather than the courts, given the constitutional structure. Whether that happens in the next parliamentary session or the one after that is genuinely hard to predict. The bill history suggests political appetite exists; whether it reaches a majority is another matter entirely.

Sources

• Commission on Narcotic Drugs 63rd Session Reconvened, UNODC
• Cannabis regulation in Africa: a review of policies; NCBI / PubMed Central
• World Drug Report 2023: Drug Supply, UNODC
• National Drug Law Enforcement Agency, NDLEA Nigeria

, Marcus Hale, Regulatory researcher; TGA & access law